These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 28539475)

  • 1. The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.
    Kodack DP; Askoxylakis V; Ferraro GB; Sheng Q; Badeaux M; Goel S; Qi X; Shankaraiah R; Cao ZA; Ramjiawan RR; Bezwada D; Patel B; Song Y; Costa C; Naxerova K; Wong CSF; Kloepper J; Das R; Tam A; Tanboon J; Duda DG; Miller CR; Siegel MB; Anders CK; Sanders M; Estrada MV; Schlegel R; Arteaga CL; Brachtel E; Huang A; Fukumura D; Engelman JA; Jain RK
    Sci Transl Med; 2017 May; 9(391):. PubMed ID: 28539475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.
    Trono P; Di Modugno F; Circo R; Spada S; Di Benedetto A; Melchionna R; Palermo B; Matteoni S; Soddu S; Mottolese M; De Maria R; Nisticò P
    Oncogene; 2016 Feb; 35(7):887-96. PubMed ID: 25961924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
    Yao E; Zhou W; Lee-Hoeflich ST; Truong T; Haverty PM; Eastham-Anderson J; Lewin-Koh N; Gunter B; Belvin M; Murray LJ; Friedman LS; Sliwkowski MX; Hoeflich KP
    Clin Cancer Res; 2009 Jun; 15(12):4147-56. PubMed ID: 19509167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer.
    Da Silva L; Simpson PT; Smart CE; Cocciardi S; Waddell N; Lane A; Morrison BJ; Vargas AC; Healey S; Beesley J; Pakkiri P; Parry S; Kurniawan N; Reid L; Keith P; Faria P; Pereira E; Skalova A; Bilous M; Balleine RL; Do H; Dobrovic A; Fox S; Franco M; Reynolds B; Khanna KK; Cummings M; Chenevix-Trench G; Lakhani SR
    Breast Cancer Res; 2010; 12(4):R46. PubMed ID: 20604919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profiling the HER3/PI3K pathway in breast tumors using proximity-directed assays identifies correlations between protein complexes and phosphoproteins.
    Mukherjee A; Badal Y; Nguyen XT; Miller J; Chenna A; Tahir H; Newton A; Parry G; Williams S
    PLoS One; 2011 Jan; 6(1):e16443. PubMed ID: 21297994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3.
    Ruiz-Saenz A; Dreyer C; Campbell MR; Steri V; Gulizia N; Moasser MM
    Cancer Res; 2018 Jul; 78(13):3645-3658. PubMed ID: 29760043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
    Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
    Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
    Araki K; Miyoshi Y
    Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
    Miller JA; Kotecha R; Ahluwalia MS; Mohammadi AM; Chao ST; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
    Cancer; 2017 Jun; 123(12):2283-2293. PubMed ID: 28192598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
    Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
    Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B.
    Kirouac DC; Du J; Lahdenranta J; Onsum MD; Nielsen UB; Schoeberl B; McDonagh CF
    PLoS Comput Biol; 2016 Apr; 12(4):e1004827. PubMed ID: 27035903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.
    Saunus JM; Quinn MC; Patch AM; Pearson JV; Bailey PJ; Nones K; McCart Reed AE; Miller D; Wilson PJ; Al-Ejeh F; Mariasegaram M; Lau Q; Withers T; Jeffree RL; Reid LE; Da Silva L; Matsika A; Niland CM; Cummings MC; Bruxner TJ; Christ AN; Harliwong I; Idrisoglu S; Manning S; Nourse C; Nourbakhsh E; Wani S; Anderson MJ; Fink JL; Holmes O; Kazakoff S; Leonard C; Newell F; Taylor D; Waddell N; Wood S; Xu Q; Kassahn KS; Narayanan V; Taib NA; Teo SH; Chow YP; kConFab ; Jat PS; Brandner S; Flanagan AM; Khanna KK; Chenevix-Trench G; Grimmond SM; Simpson PT; Waddell N; Lakhani SR
    J Pathol; 2015 Nov; 237(3):363-78. PubMed ID: 26172396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
    Merino VF; Cho S; Liang X; Park S; Jin K; Chen Q; Pan D; Zahnow CA; Rein AR; Sukumar S
    Mol Oncol; 2017 May; 11(5):552-566. PubMed ID: 28296140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway.
    Münster PN; Marchion DC; Basso AD; Rosen N
    Cancer Res; 2002 Jun; 62(11):3132-7. PubMed ID: 12036925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.
    Bieniasz M; Radhakrishnan P; Faham N; De La O JP; Welm AL
    Clin Cancer Res; 2015 Dec; 21(24):5588-600. PubMed ID: 26289070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2-Positive Breast Cancer.
    Kanthala S; Banappagari S; Gokhale A; Liu YY; Xin G; Zhao Y; Jois S
    Chem Biol Drug Des; 2015 Jun; 85(6):702-714. PubMed ID: 25346057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin.
    Campbell MR; Zhang H; Ziaee S; Ruiz-Saenz A; Gulizia N; Oeffinger J; Amin DN; Ahuja D; Moasser MM; Park CC
    Breast Cancer Res Treat; 2016 Feb; 155(3):431-40. PubMed ID: 26860947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
    Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
    Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients.
    Berghoff AS; Bartsch R; Preusser M; Ricken G; Steger GG; Bago-Horvath Z; Rudas M; Streubel B; Dubsky P; Gnant M; Fitzal F; Zielinski CC; Birner P
    Breast; 2014 Oct; 23(5):637-43. PubMed ID: 25017122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Keeping It in the Family: HER3 as a Target in Brain Metastases.
    Kabraji S; Lin NU
    Clin Cancer Res; 2023 Aug; 29(16):2961-2963. PubMed ID: 37306554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.